BDX - Becton Dickinson and Company - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0758871091
Medical Devices, Laboratory Equipment, Diagnostic Products, Syringes, Needles
Becton, Dickinson and Company is a global leader in the medical technology industry, providing a wide range of innovative products and solutions to healthcare institutions, physicians, researchers, and the general public worldwide.
The company operates through three main segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical focuses on developing and manufacturing medical supplies, devices, and equipment for various healthcare settings. This includes products such as IV catheters, syringes, needles, and medication delivery systems, as well as solutions for medication safety, infusion therapy, and supply management.
In addition to medical supplies, BD Medical also offers a range of products for vascular access, anesthesia, and enteral nutrition, as well as systems for medication compounding, automated dispensing, and inventory management. This segment is dedicated to improving patient care and safety, while also enhancing the efficiency and effectiveness of healthcare providers.
BD Life Sciences, on the other hand, is focused on advancing the discovery and diagnosis of diseases. This segment offers a broad portfolio of products and solutions for specimen collection, blood and tuberculosis culturing, molecular testing, and microbiology laboratory automation. BD Life Sciences also provides a range of reagents, antibodies, and kits for gene expression analysis, as well as diagnostic and monitoring tools for clinical oncology, immunology, and transplantation.
The BD Interventional segment is dedicated to developing and manufacturing innovative products for surgical and interventional procedures. This includes hernia and soft tissue repair products, biological and bioresorbable grafts, biosurgery products, and surgical infection prevention solutions. The segment also offers peripheral intervention products, urology and critical care products, and other surgical solutions designed to improve patient outcomes and reduce healthcare costs.
With a rich history dating back to 1897, Becton, Dickinson and Company is headquartered in Franklin Lakes, New Jersey, and is committed to advancing the world of health through innovative solutions and partnerships. To learn more about the company and its products, visit https://www.bd.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
BDX Stock Overview
Market Cap in USD | 67,419m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC SubIndustry | Health Care Equipment |
TER | 0.00% |
IPO / Inception | 1987-01-01 |
BDX Stock Ratings
Growth 5y | 8.51 |
Fundamental | 31.4 |
Dividend | 40.0 |
Rel. Performance vs Sector | -0.82 |
Analysts | 4.24/5 |
Fair Price Momentum | 223.28 USD |
Fair Price DCF | 278.09 USD |
BDX Dividends
Dividend Yield 12m | 1.60% |
Yield on Cost 5y | 1.68% |
Dividends CAGR 5y | 4.02% |
Payout Consistency | 79.2% |
BDX Growth Ratios
Growth 12m | -7.74% |
Growth Correlation 12m | -27% |
Growth Correlation 3m | 52% |
CAGR 5y | 0.98% |
CAGR/Mean DD 5y | 0.09 |
Sharpe Ratio 12m | -0.64 |
Alpha vs SP500 12m | -26.15 |
Beta vs SP500 5y weekly | 0.45 |
ValueRay RSI | 66.51 |
Volatility GJR Garch 1y | 18.09% |
Price / SMA 50 | 0.95% |
Price / SMA 200 | 1.36% |
Current Volume | 712.9k |
Average Volume 20d | 1284.9k |
External Links for BDX Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of October 05, 2024, the stock is trading at USD 238.22 with a total of 712,860 shares traded.
Over the past week, the price has changed by -1.36%, over one month by +1.21%, over three months by +5.02% and over the past year by -8.92%.
According to ValueRays Forecast Model, BDX Becton Dickinson and Company will be worth about 241.2 in October 2025. The stock is currently trading at 238.22. This means that the stock has a potential upside of +1.23%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 273.4 | 14.8 |
Analysts Target Price | 301.2 | 26.4 |
ValueRay Target Price | 241.2 | 1.23 |